Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to understand more about why some patients choose to have surgery to treat their papillary microcarcinoma (PMC) and others choose to have their papillary microcarcinoma (PMC) regularly watched by their doctor to see if and when they may need surgery (referred to as "active surveillance"). The investigators also hope learn more about what patients and their family members worry about or feel they will gain from surgery or active surveillance.
| Condition | Intervention |
|---|---|
|
Thyroid Cancer Papillary Microcarcinoma |
Behavioral: Focus groups |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based Time Perspective: Prospective |
| Official Title: | Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others |
- To explore patients' and families' perceived risks and benefits of active surveillance and surgery within the context of papillary microcarcinoma. [ Time Frame: 5 years ] [ Designated as safety issue: No ]We'll conduct focus groups & individual interviews with 2 population segments established by the method of Krueger & Casey & Morgan. The population segments will be thyroid cancer patients who have had surg or have scheduled surg, & any pt-designated significant others who assisted pts with tx decision-making & thyroid cancer pts who chose to not have immediate surg, whether they are either postponing their tx decision until a later date, or have committed to active surveillance rather than surg, & any pt-designated significant others who assisted these patients with tx decision-making.
- To examine the factors in patients' and families' decision making about the treatment of papillary microcarcinoma. [ Time Frame: 5 years ] [ Designated as safety issue: No ]We'll conduct focus groups & individual interviews with 2 population segments established by the method of Krueger & Casey & Morgan. The population segments will be thyroid cancer pts who have had surg or have scheduled surg, & any pt-designated significant others who assisted patients with tx decision-making & thyroid cancer pts who chose to not have immediate surg, whether they are either postponing their tx decision until a later date, or have committed to active surveillance rather than surg, & any patient-designated significant others who assisted these pts with tx decision-making.
| Estimated Enrollment: | 60 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | June 2016 |
| Estimated Primary Completion Date: | June 2016 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
patients who have had surgery or have scheduled surgery
In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
|
Behavioral: Focus groups
The focus groups will cover the following issues
Other Names:
|
|
who chose to not have immediate surgery
In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
|
Behavioral: Focus groups
The focus groups will cover the following issues:
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
All participants will be recruited from Dr. Mike Tuttle's clinic.
Inclusion Criteria:
Thyroid cancer patient eligibility will include:
- Thyroid cancer patients who have been diagnosed with papillary microcarcinoma (or subcentimeter thyroid lesions with fine needle aspiration biopsy suspicious for papillary or follicular thyroid cancer) within the prior 6-12 months as per EMR path report and clinician assessment;
- Presented with the option of treating their papillary microcarcinomas with either surgery or active surveillance as per treating physician;
- English-fluent;
- 18 years of age or older;
Patient-designated significant other eligibility will include:
- Nomination by patient as individual who assisted patient in decision-making regarding how to treat thyroid papillary microcarcinoma;
- English-fluent;
- 18 years of age or older;
Exclusion Criteria:
Thyroid cancer patient exclusion criteria will include:
- Thyroid cancer patients with known loco-regional or distant metastases prior to initial surgical intervention as per path report.
Contacts and Locations| Contact: Carma Bylund-Lincoln, PhD | 646-888-0210 | |
| Contact: Michael Tuttle, MD | 646-888-2716 |
| United States, New York | |
| Memorial Sloan Kettering Cancer Center | Recruiting |
| New York, New York, United States, 10065 | |
| Contact: Carma Bylund-Lincoln, PhD 646-888-0210 | |
| Contact: Michaell Tuttle, MD 646-888-2716 | |
| Principal Investigator: Carma Bylund-Lincoln, PhD | |
| Principal Investigator: | Carma Bylund-Lincoln, PhD | Memorial Sloan-Kettering Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Memorial Sloan-Kettering Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01392222 History of Changes |
| Other Study ID Numbers: | 11-108 |
| Study First Received: | June 29, 2011 |
| Last Updated: | April 24, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Memorial Sloan-Kettering Cancer Center:
|
focus group 11-108 |
Additional relevant MeSH terms:
|
Thyroid Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms |
Head and Neck Neoplasms Endocrine System Diseases Thyroid Diseases |
ClinicalTrials.gov processed this record on May 16, 2013